- Home
- NMRK vs CDTX Comparison
NMRK vs CDTX Comparison
Compare NMRK & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRK
- CDTX
- Stock Information
- Founded
- NMRK 1929
- CDTX 2012
- Country
- NMRK United States
- CDTX United States
- Employees
- NMRK N/A
- CDTX N/A
- Industry
- NMRK Real Estate
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NMRK Finance
- CDTX Health Care
- Exchange
- NMRK Nasdaq
- CDTX Nasdaq
- Market Cap
- NMRK 3.1B
- CDTX 2.8B
- IPO Year
- NMRK 2017
- CDTX 2015
- Fundamental
- Price
- NMRK $17.53
- CDTX $219.72
- Analyst Decision
- NMRK Strong Buy
- CDTX Buy
- Analyst Count
- NMRK 5
- CDTX 13
- Target Price
- NMRK $19.00
- CDTX $119.44
- AVG Volume (30 Days)
- NMRK 1.4M
- CDTX 2.2M
- Earning Date
- NMRK 10-30-2025
- CDTX 11-06-2025
- Dividend Yield
- NMRK 0.69%
- CDTX N/A
- EPS Growth
- NMRK 94.50
- CDTX N/A
- EPS
- NMRK 0.59
- CDTX N/A
- Revenue
- NMRK $3,160,782,000.00
- CDTX N/A
- Revenue This Year
- NMRK $19.70
- CDTX N/A
- Revenue Next Year
- NMRK $9.58
- CDTX N/A
- P/E Ratio
- NMRK $29.57
- CDTX N/A
- Revenue Growth
- NMRK 20.95
- CDTX N/A
- 52 Week Low
- NMRK $9.65
- CDTX $15.22
- 52 Week High
- NMRK $19.84
- CDTX $220.46
- Technical
- Relative Strength Index (RSI)
- NMRK 53.98
- CDTX 88.61
- Support Level
- NMRK $15.29
- CDTX $218.86
- Resistance Level
- NMRK $17.61
- CDTX $220.46
- Average True Range (ATR)
- NMRK 0.64
- CDTX 3.01
- MACD
- NMRK 0.11
- CDTX 6.76
- Stochastic Oscillator
- NMRK 94.84
- CDTX 99.39
About NMRK Newmark Group Inc.
Newmark Group Inc is a commercial real estate advisory firm. It offers services, including leasing and corporate advisory services, investment sales, commercial mortgage brokerage, appraisal and valuation, project management, and property, among others. Newmark offers a diverse array of integrated services and products designed to meet the full needs of both real estate investors/owners and occupiers. The company provides real estate strategic consulting and systems integration services to CFI's clients including many Fortune and Forbes companies, owner-occupiers, government agencies, healthcare, and higher education clients.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.